iTheranostics, Novartis ink FAP-targeted drug development agreement

Sofie subsidiary iTheranostics has inked an agreement with Novartis to collaborat...Read more on AuntMinnie.comRelated Reading: Novartis touts phase III prostate cancer study results SNMMI celebrates 60th anniversary with special issue Jubilant inks deal to invest $25M in Sofie Novartis to buy Endocyte for $2.1B SNMMI: Theranostic agent awarded Image of the Year
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news